Evidence map›Paper›PMID 25079364›Full record

ArticlePloS one2014

Development and validation of a fast and optimized screening method for enhanced production of secondary metabolites using the marine Scopulariopsis brevicaulis strain LF580 producing anti-cancer active scopularide A and B.

Annemarie Kramer, Linda Paun, Johannes F Imhoff, Frank Kempken, Antje Labes

Abstract readValidation Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Proteogenomics for Non-model Ocean-Derived Fungi.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Antitumor Potential of Seaweed Derived-Endophytic Fungi.Antibiotics (Basel, Switzerland) · 2019
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Annemarie KramerKiel Centre for Marine Natural Products at GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany.
Linda PaunDepartment of Genetics and Molecular Biology in Botany, Institute of Botany, Christians-Albrechts-University, Kiel, Germany.
Johannes F ImhoffKiel Centre for Marine Natural Products at GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany.
Frank KempkenDepartment of Genetics and Molecular Biology in Botany, Institute of Botany, Christians-Albrechts-University, Kiel, Germany.
Antje LabesKiel Centre for Marine Natural Products at GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural compounds from marine fungi are an excellent source for the discovery and development of new drug leads. The distinct activity profiles of the two cyclodepsipeptides scopularide A and B against cancer cell lines set their marine producer strain Scopulariopsis brevicaulis LF580 into the focus of the EU project MARINE FUNGI. One of the main goals was the development of a sustainable biotechnological production process for these compounds. The secondary metabolite production of strain LF580 was optimized by random mutagenesis employing UV radiation. For a fast and reliable detection of the intracellular secondary metabolite production level, a miniaturized bioactivity-independent screening method was developed, as the random mutagenesis yielded a large number of mutants to be analysed quantitatively and none of the existing hyphenated bioassay-dependent screening systems could be applied. The method includes decreased cultivation volume, a fast extraction procedure as well as an optimized LC-MS analysis. We show that deviation could be specifically reduced at each step of the process: The measuring deviation during the analysis could be minimized to 5% and technical deviation occurring in the downstream part to 10-15%. Biological variation during the cultivation process still has the major influence on the overall variation. However, the approach led to a 10-fold reduction of time and similar effects on costs and effort compared to standard reference screening methods. The method was applied to screen the UV-mutants library of Scopulariopsis brevicaulis LF580. For validation purposes, the occurring variations in the miniaturized scale were compared to those in the classical Erlenmeyer flask scale. This proof of concept was performed using the wild type strain and 23 randomly selected mutant strains. One specific mutant strain with an enhanced production behavior could be obtained.

Indexed as

Marine BiologyAntineoplastic AgentsChromatography, LiquidDepsipeptidesMass SpectrometryMiniaturizationScopulariopsisAntineoplastic AgentsDepsipeptidesscopularide Ascopularide B

Identifiers

PMID25079364
PMCPMC4117492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.